AU Patent

AU2019201811B2 — Methods of therapeutic monitoring of phenylacetic acid prodrugs

Assigned to Immedica Pharma AB · Expires 2020-07-09 · 6y expired

What this patent protects

The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

USPTO Abstract

The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019201811B2
Jurisdiction
AU
Classification
—
Expires
2020-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Immedica Pharma AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.